Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007)
Status:
Completed
Trial end date:
2017-06-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics and lung penetration of
intravenous Ceftolozane/tazobactam in critically ill participants.
Phase:
Phase 1
Details
Lead Sponsor:
Cubist Pharmaceuticals LLC
Treatments:
Ceftolozane Ceftolozane, tazobactam drug combination Cephalosporins Penicillanic Acid Tazobactam